These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21439441)

  • 1. Natural history of multiple sclerosis: early prognostic factors.
    Mowry EM
    Neurol Clin; 2011 May; 29(2):279-92. PubMed ID: 21439441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of multiple sclerosis: long-term prognostic factors.
    Renoux C
    Neurol Clin; 2011 May; 29(2):293-308. PubMed ID: 21439442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of multiple sclerosis: risk factors and prognostic indicators.
    Vukusic S; Confavreux C
    Curr Opin Neurol; 2007 Jun; 20(3):269-74. PubMed ID: 17495619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Towards a reliable prognosis for multiple sclerosis].
    Heinzlef O; Roullet E
    Rev Prat; 1999 Nov; 49(17):1872-5. PubMed ID: 10598503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evoked potential abnormality scores are a useful measure of disease burden in relapsing-remitting multiple sclerosis.
    O'Connor P; Marchetti P; Lee L; Perera M
    Ann Neurol; 1998 Sep; 44(3):404-7. PubMed ID: 9749611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Course of illness and prognosis of multiple sclerosis. 2: Predictive value of clinical and paraclinical factors].
    Flachenecker P; Hartung HP
    Nervenarzt; 1996 Jun; 67(6):444-51. PubMed ID: 8767198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The natural history of multiple sclerosis.
    Deshpande R; Kremenchutzky M; Rice GP
    Adv Neurol; 2006; 98():1-15. PubMed ID: 16400823
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis.
    Losseff NA; Kingsley DP; McDonald WI; Miller DH; Thompson AJ
    Mult Scler; 1996 Feb; 1(4):218-22. PubMed ID: 9345438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis.
    Minneboo A; Barkhof F; Polman CH; Uitdehaag BM; Knol DL; Castelijns JA
    Arch Neurol; 2004 Feb; 61(2):217-21. PubMed ID: 14967769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive markers of disease evolution after a CIS in everyday practice.
    Arrambide G; Sastre-Garriga J
    J Neurol Sci; 2014 Aug; 343(1-2):8-14. PubMed ID: 24881867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately--no.
    Filippi M; Rocca MA
    Mult Scler; 2012 May; 18(5):557-8. PubMed ID: 22547411
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic indicators for long-term disability in multiple sclerosis patients.
    Damasceno A; Von Glehn F; Brandão CO; Damasceno BP; Cendes F
    J Neurol Sci; 2013 Jan; 324(1-2):29-33. PubMed ID: 23073568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately--yes.
    Geurts JJ
    Mult Scler; 2012 May; 18(5):559-60. PubMed ID: 22547412
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision.
    Bergamaschi R
    Expert Rev Neurother; 2006 Mar; 6(3):357-64. PubMed ID: 16533140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Starting early: MRI evidence of gray matter atrophy in children with multiple sclerosis.
    Banwell BL; Sled JG
    Neurology; 2008 Mar; 70(13 Pt 2):1065-6. PubMed ID: 18362266
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognosis of the individual course of disease: the elements of time, heterogeneity and precision.
    Daumer M; Neuhaus A; Herbert J; Ebers G
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S50-5. PubMed ID: 20106349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
    Roxburgh RH; Seaman SR; Masterman T; Hensiek AE; Sawcer SJ; Vukusic S; Achiti I; Confavreux C; Coustans M; le Page E; Edan G; McDonnell GV; Hawkins S; Trojano M; Liguori M; Cocco E; Marrosu MG; Tesser F; Leone MA; Weber A; Zipp F; Miterski B; Epplen JT; Oturai A; Sørensen PS; Celius EG; Lara NT; Montalban X; Villoslada P; Silva AM; Marta M; Leite I; Dubois B; Rubio J; Butzkueven H; Kilpatrick T; Mycko MP; Selmaj KW; Rio ME; Sá M; Salemi G; Savettieri G; Hillert J; Compston DA
    Neurology; 2005 Apr; 64(7):1144-51. PubMed ID: 15824338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the natural history and prognostic features of early onset and adult onset multiple sclerosis in Jordanian population.
    El-Salem K; Khader Y
    Clin Neurol Neurosurg; 2007 Jan; 109(1):32-7. PubMed ID: 16870328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton MR spectroscopy in multiple sclerosis.
    Arnold DL; De Stefano N; Narayanan S; Matthews PM
    Neuroimaging Clin N Am; 2000 Nov; 10(4):789-98 ,ix-x. PubMed ID: 11359725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.